Document is current
Any future updates will be listed below
-
Authors
Gonzalez-Martinez, David https://orcid.org/0000-0003-1782-9133
Roth, Lee https://orcid.org/0000-0001-9290-2463
Mumford, Thomas R.
Guan, Juan
Le, Anh
Doebele, Robert C. https://orcid.org/0000-0001-6728-6857
Huang, Bo https://orcid.org/0000-0003-1704-4141
Tulpule, Asmin
Niewiadomska-Bugaj, Magdalena
Bivona, Trever G. https://orcid.org/0000-0001-5734-4128
Bugaj, Lukasz J. https://orcid.org/0000-0002-0749-2912
-
Funding
Funding for this research was provided by:
American Cancer Society (RSG-22-176-01-TBE)
- License Information
-
More Information
Article History
Received: 6 July 2024
Accepted: 12 October 2024
First Online: 2 November 2024
Competing interests
: D.G.M. and L.J.B. have filed a provisional patent based on the findings in this work. T.G.B. is an advisor to Novartis, AstraZeneca, Revolution Medicines, Array/Pfizer, Springworks, Strategia, Relay, Jazz, Rain, Engine, Scorpion and receives research funding from Strategia, Kinnate, Verastem, and Revolution Medicines. A.T. is an advisor to Faze Medicines. R.C.D. is an employee and shareholder of Rain Oncology Inc. and has received licensing fees from Takeda, ThermoFisher, Voronoi, Loxo, Histocyte, and Black Diamond. The remaining authors declare no competing interests.
